Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical drug conjugate using Starpharma’s DEP® platform technology. This collaboration marks a significant strategic step for Radiopharm in advancing targeted cancer therapies and offers Starpharma the potential for substantial financial returns through licensing fees and milestone payments, highlighting the impact on both companies’ operations and their positions in the oncology market.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics is a clinical-stage biopharmaceutical company specializing in developing innovative radiopharmaceutical products for oncology, focusing on areas with high unmet medical needs. The company is listed on ASX and NASDAQ and has a diverse pipeline of technologies including peptides, small molecules, and monoclonal antibodies for cancer treatment.
Average Trading Volume: 3,947,480
Technical Sentiment Signal: Hold
Current Market Cap: A$68.58M
For an in-depth examination of RAD stock, go to TipRanks’ Overview page.